Avalo Therapeutics (AVTX) EBT Margin (2016 - 2025)
Avalo Therapeutics posted quarterly EBT Margin of 23033.9% for Q4 2025, down 468754.0% year-on-year from N/an in Q4 2024, and down 25.55% on a QoQ basis from 18346.35% in Q4 2024.
Avalo Therapeutics (AVTX) has 10 years of EBT Margin data on file, last reported at 23033.9% in Q4 2025.
- For the quarter ending Q4 2025, EBT Margin fell 468754.0% year-over-year to 23033.9%; the trailing twelve-month figure through Dec 2025 stood at 15618.8% (down 767889.0% YoY), and the FY2025 full-year result was 132362.71%, down 12442280.0% from the prior year.
- EBT Margin for Q4 2025 stood at 23033.9%, down from 18346.35% in the prior quarter.
- Across five years, EBT Margin topped out at 9246.18% in Q3 2024 and bottomed at 23033.9% in Q4 2025.
- The 5-year median for EBT Margin is 1432.05% (2023), against an average of 4024.64%.
- Peak annual rise in EBT Margin reached 1145805 bps in 2024, while the deepest fall reached 1691431 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 8742.92% in 2021, then soared by 87 bps to 1094.2% in 2022, then slumped by 31 bps to 1432.05% in 2023, then plunged by 1181 bps to 18346.35% in 2024, then decreased by 26 bps to 23033.9% in 2025.
- The last three EBT Margin figures came in at 23033.9% (Q4 2025), 18346.35% (Q4 2024), and 9246.18% (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -23,033.90% |
| Dec 31, 2024 | -18,346.35% |
| Sep 30, 2024 | 9,246.18% |
| Dec 31, 2023 | -1,432.05% |
| Sep 30, 2023 | -2,211.86% |
| Jun 30, 2023 | -1,273.09% |
| Mar 31, 2023 | -2,094.11% |
| Dec 31, 2022 | -1,094.20% |
| Sep 30, 2022 | 21.39% |
| Jun 30, 2022 | -1,256.73% |
| Mar 31, 2022 | -1,879.11% |
| Dec 31, 2021 | -8,742.92% |
| Sep 30, 2021 | -1,293.56% |
| Jun 30, 2021 | -517.82% |
| Mar 31, 2021 | -6,461.52% |
| Dec 31, 2020 | -1,090.71% |
| Sep 30, 2020 | -1,193.34% |
| Jun 30, 2020 | -992.53% |
| Mar 31, 2020 | -882.79% |
| Dec 31, 2019 | -974.36% |
| Sep 30, 2019 | -127.60% |
| Jun 30, 2019 | -178.94% |
| Mar 31, 2019 | -195.30% |
| Dec 31, 2018 | 14.60% |
| Sep 30, 2018 | -602.51% |
| Jun 30, 2018 | -125.20% |
| Mar 31, 2018 | -86.09% |
| Dec 31, 2017 | -227.90% |
| Sep 30, 2017 | 87.67% |
| Jun 30, 2017 | -1,139.74% |
| Mar 31, 2017 | -510.31% |
| Dec 31, 2016 | -900.39% |
| Sep 30, 2016 | -1,918.75% |
| Jun 30, 2016 | -555.74% |